Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
of KEYNOTE trials 059 and 180. | Download Scientific Diagram
KEYNOTE 062: Pembrolizumab in first line treatment of advanced gastric ...
ASCO GU 2019: Keynote 057: Phase II trial of Pembrolizumab for Patients ...
ASCO GU 2019: Updated Results of Keynote 057: Pembrolizumab for ...
Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE ...
KEYNOTE059 Cohort 1 Pembrolizumab Monotherapy in Previously Treated
重磅：免疫療法再下一城！FDA批准默沙東Keytruda用於晚期胃癌！ - 每日頭條
Subanalysis of KEYNOTE-059, -061, and -062 - The ASCO Post
(PDF) Safety and Efficacy of Pembrolizumab Monotherapy in Patients With ...
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With ...
(PDF) Pembrolizumab alone or in combination with chemotherapy as first ...
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite ...
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric ...
(PDF) Efficacy of Pembrolizumab Monotherapy in Japanese Patients with ...
(PDF) LBA28_PRKEYNOTE-059 Update: Efficacy and safety of pembrolizumab ...
KEYNOTE-905: EV + Pembrolizumab Boosts Survival in MIBC
ASCO GU 2022: Post Hoc Analysis of the Efficacy of Pembrolizumab ...
Survival Benefits Achieved With Pembrolizumab in Some Gastric and ...
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib ...
ASCO GU 2022: Impact of Primary Tumor Location on Efficacy and Safety ...
ASCO 2023: First-Line Lenvatinib + Pembrolizumab Treatment Across Non ...
ASCO GU 2022: First-Line Pembrolizumab in Advanced Urothelial Carcinoma ...
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder ...
Efficacy and safety of pembrolizumab for the treatment of advanced ...
進行食道胃接合部癌および胃癌に対するPembrolizumabの安全性と有効性を評価したマルチコホート第II相試験（KEYNOTE-059試験 ...
Pembrolizumab in patients with advanced non-small-cell lung cancer ...
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with ...
(PDF) Safety and efficacy of pembrolizumab in combination with S-1 plus ...
(PDF) Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as ...
Updated efficacy and safety of KEYNOTE-224: a phase II study of ...
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma ...
Safety and clinical activity of pembrolizumab for treatment of ...
ASCO GU 2023: Phase 3 KEYNOTE-905/EV-303: Perioperative Pembrolizumab ...
First-line pembrolizumab in cisplatin-ineligible patients with locally ...
Pembrolizumab (Keytruda)
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced ...
ASCO 2025: Five-Year Follow-up Results from the Phase 3 KEYNOTE-564 ...
Pembrolizumab alone or in combination with chemotherapy as first-line ...
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small ...
ESMO Virtual Congress 2020: Pembrolizumab Combined with Chemotherapy vs ...
Tumor dynamics in patients with solid tumors treated with pembrolizumab ...
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous ...
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for ...
ASCO GU 2023: Pembrolizumab Monotherapy for Patients with High-Risk Non ...
Pembrolizumab for Locally Advanced or Recurrent/Metastatic Cutaneous ...
(PDF) KEYNOTE-590: Phase III study of first-line chemotherapy with or ...
Pembrolizumab monotherapy for the treatment of high-risk non-muscle ...
First-line pembrolizumab with or without chemotherapy for recurrent or ...
FDA Grants Priority Review to Merck’s Application for KEYTRUDA ...
ASCO GU 2023: Adjuvant Pembrolizumab for Renal Cell Carcinoma (RCC ...
First-line pembrolizumab + chemotherapy in Japanese patients with ...
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy ...
(PDF) Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular ...
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer ...
Biomarker-directed, pembrolizumab-based combination therapy in non ...
Pembrolizumab plus chemotherapy versus chemotherapy alone for first ...
Full article: Perioperative Pembrolizumab Therapy in Muscle-Invasive ...
ASCO 2020: KEYNOTE-426: Pembrolizumab plus Axitinib versus Sunitinib as ...
Phase II study of cabozantinib (cabo) combined with pembrolizumab ...
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced ...
Pembrolizumab in combination with gemcitabine and cisplatin compared ...
ASCO GU 2019: Phase III KEYNOTE-426 Study: Pembrolizumab plus Axitinib ...
ASCO 2023: Outcomes by Complete Response to First-Line Pembrolizumab or ...
A phase 2 study of trastuzumab in combination with S-1 and cisplatin in ...
KEYNOTE-689: Pembrolizumab Boosts Survival in HNSCC
(PDF) Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung ...
(PDF) Pembrolizumab (pembro) as first-line therapy for advanced ...
Pembrolizumab versus placebo as adjuvant therapy for completely ...
Pembrolizumab plus chemotherapy versus chemotherapy for advanced ...
Figure 1 from Pembrolizumab or pembrolizumab plus chemotherapy versus ...
(PDF) Quality of life with first-line pembrolizumab for PD-L1-positive ...
(PDF) Safety and Antitumor Activity of Pembrolizumab in Advanced ...
(PDF) Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non ...
ASCO 2021: First-Line Pembrolizumab (Pembro) in Cisplatin-Ineligible ...
(PDF) KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy ...
(PDF) KEYNOTE-975 Study Design: a Phase III Study of Definitive ...
(PDF) Cost-Effectiveness Analysis of Pembrolizumab in Patients With ...
Safety and efficacy of pembrolizumab monotherapy in elderly patients ...
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for ...
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma ...
00178-5/asset/aab0df13-8c24-4a9d-82e1-8ea968576500/main.assets/gr2_lrg.jpg)
30066-3/asset/9fbc24c5-e34e-411c-8496-cae29baf07e7/main.assets/gr1.gif)
30066-3/asset/5baa6f47-0697-4156-aa1d-f95c10094a2e/main.assets/gr4_lrg.jpg)
00175-3/asset/21d0398a-7e3d-4d7b-bb8e-973ea34fc588/main.assets/gr1_lrg.jpg)
